BioLineRx (BLRX) Income from Continuing Operations (2013 - 2025)
BioLineRx (BLRX) recorded quarterly Income from Continuing Operations of 3106000.0 in Q4 2025, down 318.6% quarter-over-quarter from 742000.0 in Q3 2025, and down 5851.85% on a YoY basis from 54000.0 in Q4 2024.
BioLineRx (BLRX) Income from Continuing Operations (2013 - 2025) Analysis & Trends
BioLineRx's Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 3106000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 5851.85% year-over-year to 3106000.0; the TTM figure through Dec 2025 stood at 6768000.0 (up 16.34% YoY), while the FY2025 annual figure was 7543000.0, up 19.91% from the prior year.
- Income from Continuing Operations was 3106000.0 for Q4 2025 at BioLineRx, down from 742000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 54000.0 in Q4 2024 to a low of 19498000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 5460850.0 across 5 years, with a median of 5741500.0 in 2021.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 100.28% in 2024, then slumped 5851.85% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6394000.0 in 2021, then retreated by 10.6% to 7072000.0 in 2022, then slumped by 175.71% to 19498000.0 in 2023, then soared by 100.28% to 54000.0 in 2024, then plunged by 5851.85% to 3106000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 3106000.0 (Q4 2025), 742000.0 (Q3 2025), and 1243000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.11 Mn |
| Sep 30, 2025 | -742,000.00 |
| Jun 30, 2025 | -1.24 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | -2.23 Mn |
| Jun 30, 2024 | -2.59 Mn |
| Mar 31, 2024 | -3.33 Mn |
| Dec 31, 2023 | -19.50 Mn |
| Sep 30, 2023 | -10.23 Mn |
| Jun 30, 2023 | -7.60 Mn |
| Mar 31, 2023 | -7.39 Mn |
| Dec 31, 2022 | -7.07 Mn |
| Sep 30, 2022 | -6.56 Mn |
| Jun 30, 2022 | -7.08 Mn |
| Mar 31, 2022 | -5.83 Mn |
| Dec 31, 2021 | -6.39 Mn |
| Sep 30, 2021 | -5.66 Mn |
| Jun 30, 2021 | -6.02 Mn |
| Mar 31, 2021 | -5.03 Mn |